Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Issue 9 (17th December 2021)

• Record Type: Journal Article
• Authors: Huang, Hsi-Chien; Sung, Yun-Chieh; Li, Chung-Pin; Wan, Dehui; Chao, Po-Han; Tseng, Yu-Ting; Liao, Bo-Wen; Cheng, Hui-Teng; Hsu, Fu-Fei; Huang, Chieh-Cheng; Chen, Yi-Ting; Liao, Yu-Hui; Hsieh, Hsin Tzu; Shih, Yu-Chuan; Liu, I-Ju; Wu, Han-Chung; Lu, Tsai-Te; Wang, Jane; Chen, Yunching
• Is Part Of: Gut. Volume 71:Issue 9(2022)
• Page Start: 1843
• Page End: 1855
• Publication Date: 2021-12-17
• Subjects: pancreatic cancer -- drug resistance -- fibrosis; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2021-325180
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Stromal barriers, such as the abundant desmoplastic stroma that is characteristic of pancreatic ductal adenocarcinoma (PDAC), can block the delivery and decrease the tumour-penetrating ability of therapeutics such as tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), which can selectively induce cancer cell apoptosis. This study aimed to develop a TRAIL-based nanotherapy that not only eliminated the extracellular matrix barrier to increase TRAIL delivery into tumours but also blocked antiapoptotic mechanisms to overcome TRAIL resistance in PDAC. Design: Nitric oxide (NO) plays a role in preventing tissue desmoplasia and could thus be delivered to disrupt the stromal barrier and improve TRAIL delivery in PDAC. We applied an in vitro–in vivo combinatorial phage display technique to identify novel peptide ligands to target the desmoplastic stroma in both murine and human orthotopic PDAC. We then constructed a stroma-targeted nanogel modified with phage display-identified tumour stroma-targeting peptides to co-deliver NO and TRAIL to PDAC and examined the anticancer effect in three-dimensional spheroid cultures in vitro and in orthotopic PDAC models in vivo . Results: The delivery of NO to the PDAC tumour stroma resulted in reprogramming of activated pancreatic stellate cells, alleviation of tumour desmoplasia and downregulation of antiapoptotic BCL-2 protein expression, thereby facilitating tumour penetration by TRAIL and substantially enhancing the antitumour efficacy of TRAIL therapy. Conclusion: The co-delivery of TRAIL and NO by a stroma-targeted nanogel that remodels the fibrotic tumour microenvironment and suppresses tumour growth has the potential to be translated into a safe and promising treatment for PDAC.